完全细胞遗传学缓解的实现对接受去甲基化药物治疗的骨髓增生异常综合征患者结局的影响
回顾性分析216例接受去甲基化药物治疗的骨髓增生异常综合征(MDS)伴异常核型患者,中位随访17个月。完全细胞遗传学缓解(CCyR)率为29%,CCyR与更好的总生存(21 vs 13个月,P=.007)和无白血病生存(16 vs 9个月,P=.001)相关,多因素分析显示CCyR是更好总生存的预测因素(HR=2.1,P<.001)。
要点
- CCyR率为29%,细胞遗传学缓解率为36%,且不总与形态学缓解相关。
- CCyR患者中位总生存21个月 vs 无CCyR者13个月(P=.007)。
- CCyR患者中位无白血病生存16个月 vs 无CCyR者9个月(P=.001)。
核心结论
- 接受去甲基化药物治疗的MDS患者细胞遗传学缓解率为36%(完全缓解29%),且不总与形态学缓解相关。
- CCyR的实现与生存改善相关,尤其在无形态学缓解的患者中构成主要预后预测因素。
- 因此,CCyR的实现应被视为MDS患者管理中的一个里程碑。
主要发现
- 最佳缓解:完全缓解(CR)79例(37%),部分缓解(PR)4例(2%),血液学改善(HI)10例(5%)。
- 细胞遗传学缓解(CyR)78例(36%):完全缓解(CCyR)62例(29%),部分缓解16例(7%)。
- CyR在CR患者中48/79例(61%),在PR/HI患者中1/14例(7%),在无形态学缓解患者中29/123例(24%)。
- 有CCyR与无CCyR患者的中位总生存分别为21个月与13个月(P=.007),中位无白血病生存分别为16个月与9个月(P=.001)。
- 多因素分析显示,CCyR的实现是更好总生存的预测因素(HR=2.1;P<.001)。
临床怎么用
- 作者认为,CCyR的实现应被视为MDS患者管理中的一个里程碑。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Two hundred and sixteen consecutive patients with MDS and abnormal karyotype treated with hypomethylating agents between 4/04 and 10/12 were reviewed. Median follow-up was 17 months. Using IWG criteria, best responses were complete response (CR) in 79 patients (37%), partial response (PR) in 4 (2%), and hematologic improvement (HI) in 10 (5%). Cytogenetic response (CyR) was achieved in 78 patients (36%): complete (CCyR) in 62 (29%) and partial in 16 (7%). CyR was achieved in 48 of 79 patients (61%) with CR, 1 of 14 (7%) with PR/HI, and in 29 of the 123 (24%) with no morphologic response. Median overall survival (OS) and leukemia-free survival (LFS) for patients with and without CCyR were 21 and 13 months (P = .007), and 16 and 9 months (P = .001), respectively. By multivariate analysis, the achievement of CCyR was predictive for better OS (HR = 2.1; P < .001). In conclusion, CyR occurs at a rate of 36% (complete in 29%) in patients with MDS treated with HMA and is not always associated with morphological response. The achievement of CCyR is associated with survival improvement and constitutes a major predictive factor for outcome particularly in patients without morphologic response. Therefore, the achievement of CCyR should be considered a milestone in the management of patients with MDS.
引用
- Jabbour E, Strati P, Cabrero M, et al. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017. PMID: 28076892. doi:10.1002/ajh.24650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。